In Pregnant Women with Type 1 Diabetes, Continuous Glucose Monitoring Linked to Better Outcomes — Physician’s First Watch
In Pregnant Women with Type 1 Diabetes, Continuous Glucose Monitoring Linked to Better Outcomes
By Joe Elia
Continuous glucose monitoring (CGM) in pregnant women with type 1 diabetes is associated with better neonatal outcomes, according to a study in The Lancet.
Researchers randomized 325 women — some in early pregnancy and some planning a pregnancy — to either capillary glucose monitoring alone or capillary monitoring plus CGM. Participants were given directions on how to use their measurements to adjust their insulin dose.
In the early-pregnancy group, the mean glycated hemoglobin level between recruitment and 34 weeks' gestation decreased significantly more with CGM than with capillary monitoring alone (-0.54 vs. -0.35). Among women planning a pregnancy, the change in hemoglobin level between recruitment and study week 24 did not differ statistically between monitoring groups.
Neonatal health (a secondary outcome) favored the CGM group. Those babies were less likely to be large-for-gestational-age and had fewer neonatal intensive care admissions than those of conventionally monitored mothers.
The Lancet's commentators write that the results "support CGM use during pregnancy for all women with type 1 diabetes."